The same signal may be beneficial early and damaging late. Testing endothelial transcytosis with pericyte-protective dosing should reveal a disease-stage interaction and define when intervention is protective versus counterproductive.
Curated pathway from expert analysis
flowchart TD
A["Endothelial Transcytosis<br/>Caveolae-Mediated Vesicular Route"]
B["Caveolin-1 Scaffold<br/>Plasma Membrane Invagination"]
C["Cargo Uptake<br/>Albumin IgG and Nanoparticles"]
D["Intracellular Trafficking<br/>Early Endosome Routing"]
E["Basolateral Release<br/>Parenchymal Delivery"]
F["Therapeutic Delivery Window<br/>Early Stage Intervention Target"]
G["Pathological Transcytosis<br/>Amyloid and Tau Seed Entry"]
A --> B
B --> C
C --> D
D --> E
D --> G
F -.->|"targets"| A
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style G fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style F fill:#1b5e20,stroke:#81c784,color:#81c784No curated PDB or AlphaFold mapping for ENDOTHELIAL yet. Search RCSB →
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for endothelial transcytosis.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
No resource usage or linked notebooks recorded for this hypothesis yet.
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF endothelial transcytosis defines the BBB therapeutic window, THEN inhibiting caveolae-mediated transcytosis early will reduce tracer leakage by >=30%, but late inhibition after gliosis will reduce | Early transcytosis inhibition reduces leakage >=30%; late inhibition reduces leakage <10% in the same model. | — no observation — | pending | 0.58 |
| IF endothelial transcytosis is upstream of neurodegeneration biomarkers, THEN endothelial vesicle markers will increase >=20% before plasma NfL rises in longitudinal at-risk cohorts. | Endothelial transcytosis EV markers rise >=20% at a visit preceding NfL increase by at least 6 months. | — no observation — | pending | 0.51 |